Company’s 36-month beta value is 0.47.Analysts have differing opinions on the stock, with 14 analysts rating it as a “buy,” 8 as “overweight,” 12 as “hold,” and 1 as “sell.”
The public float for SRPT is 93.47M, and currently, short sellers hold a 10.58% ratio of that floaft. The average trading volume of SRPT on July 01, 2025 was 5.22M shares.
SRPT) stock’s latest price update
The stock price of Sarepta Therapeutics Inc (NASDAQ: SRPT) has plunged by -0.06 when compared to previous closing price of 17.11, but the company has seen a -9.38% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-30 that NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ:SRPT) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Sarepta securities between June 22,2023 and June 24, 2025, both dates inclusive (the “Class Period”). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
SRPT’s Market Performance
SRPT’s stock has fallen by -9.38% in the past week, with a monthly drop of -55.71% and a quarterly drop of -75.71%. The volatility ratio for the week is 5.47% while the volatility levels for the last 30 days are 6.65% for Sarepta Therapeutics Inc The simple moving average for the last 20 days is -40.89% for SRPT stock, with a simple moving average of -81.57% for the last 200 days.
Analysts’ Opinion of SRPT
TD Cowen, on the other hand, stated in their research note that they expect to see SRPT reach a price target of $24. The rating they have provided for SRPT stocks is “Hold” according to the report published on June 18th, 2025.
SRPT Trading at -56.95% from the 50-Day Moving Average
After a stumble in the market that brought SRPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.51% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SRPT starting from Nicaise Claude, who sale 2,491 shares at the price of $99.64 back on Mar 12 ’25. After this action, Nicaise Claude now owns 27,812 shares of Sarepta Therapeutics Inc, valued at $248,203 using the latest closing price.
Stock Fundamentals for SRPT
Current profitability levels for the company are sitting at:
- -0.05 for the present operating margin
- 0.81 for the gross margin
The net margin for Sarepta Therapeutics Inc stands at -0.11. The total capital return value is set at -0.04. Equity return is now at value -23.61, with -7.43 for asset returns.
Based on Sarepta Therapeutics Inc (SRPT), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at -0.41. The debt to equity ratio resting at 1.18. The interest coverage ratio of the stock is -6.26.
Currently, EBITDA for the company is 333.06 million with net debt to EBITDA at -9.37. When we switch over and look at the enterprise to sales, we see a ratio of 1.25. The receivables turnover for the company is 3.08for trailing twelve months and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.02.
Conclusion
In a nutshell, Sarepta Therapeutics Inc (SRPT) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
